Related Experiment Videos
Selective D-1 dopamine receptor agonist effects in hyperkinetic extrapyramidal disorders
A Braun1, M M Mouradian, E Mohr
1Experimental Therapeutics Branch, National Institute of Neurological and Communicative Disorders and Stroke, Bethesda, MD 20892.
Summary
This study found that SKF 39393, a D-1 dopamine receptor agonist, did not consistently improve motor or cognitive symptoms in patients with hyperkinetic movement disorders. Further research is needed to understand D-1 receptor roles in these conditions.
Area of Science:
- Neuroscience
- Pharmacology
- Movement Disorders
Background:
- Hyperkinetic extrapyramidal disorders, such as Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, and torsion dystonia, are characterized by involuntary movements.
- Dopamine pathways, particularly involving D-1 receptors, are implicated in motor control and the pathophysiology of these disorders.
Purpose of the Study:
- To investigate the motor and cognitive effects of a selective D-1 dopamine receptor agonist, SKF 39393.
- To assess the potential therapeutic role of D-1 receptor modulation in hyperkinetic movement disorders.
Main Methods:
- A double-blind, placebo-controlled design was employed.
- Patients with Huntington's disease, Gilles de la Tourette's syndrome, tardive dyskinesia, and torsion dystonia received daily doses of SKF 39393 ranging from 3.2 to 32 mg/kg.
- Treatment intervals varied from one to seven weeks.
Main Results:
- No consistent motor or cognitive changes were observed in patients treated with SKF 39393.
- The administration of the D-1 dopamine receptor agonist did not yield significant therapeutic effects across the studied patient groups.
Conclusions:
- The contribution of D-1 receptor-mediated mechanisms to the pathophysiology of hyperkinetic extrapyramidal disorders remains uncertain.
- Targeting D-1 dopamine receptors with SKF 39393 is not an effective strategy for treating these movement disorders based on this study.